Trials / Completed
CompletedNCT04385407
Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients
Sofosbuvir in Combination With Ribavirin or Simeprevir: Real-life Study of Patients With Hepatitis C Genotype 4
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Beni-Suef University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A total of 201 participants with chronic HCV GT4 infection were allocated into two groups. One group participants were treated with SOF plus RBV (24 weeks). The second group was treated with SOF plus SMV (12 weeks).
Detailed description
A total of 201 participants, treatment-naïve and experienced, with chronic HCV GT4 infection were allocated into two groups based on the type of the regimen used. All eligible participants were treated orally with SOF plus daily oral weight-based RBV (24 weeks; group 1), or SOF plus daily oral SMV (12 weeks; group 2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir + Simeprevir + Ribavirin |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2020-05-12
- Last updated
- 2020-05-12
Source: ClinicalTrials.gov record NCT04385407. Inclusion in this directory is not an endorsement.